Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I dont think we'll get back that low, but i think the conclusion in the brief is very positive. Hoping they make an official release today, which should, IMO, cause it to turnaround and head back up. Might have to pick up some more if it drops lower than 1.30's!
Sunday, October 18, 2009: 9:00 AM - 11:00 AM
Hall D (Pennsylvania Convention Center)
Daniel Zimmerman, CEL SCI Corporation, Vienna, VA, Eyal Talor, CEL, Vienna, VA, Patricia Taylor, Northeastern Ohio colleges of Medicine, Rootstown, Sean O'Neill, Washington Biotech, Columbia, MD, Alison Bendele, BolderBiopath, Bolder, CO and Kenneth Rosenthal, Northeastern Ohio colleges of Medicine, Rootstown, OH
Presentation Number: 2
Poster Board Number: 2
Purpose: The collagen type II (bovine) (CIA) induced arthritis murine model is often used to evaluate treatments for rheumatoid arthritis (RA). Following initial induction, the disease progresses into a more classical cell and cytokine mediated pathogenesis. We will use this model to evaluate a new therapeutic vaccine for RA
Method: Male (7-8 week old) DBA/1J mice with CIA induced arthritis were either untreated or treated with the CEL-2000 L.E.A.P.S. experimental therapeutic vaccine or etanercept (Enbrel). CEL-2000 vaccine consists of 2 peptides of human origin, a segment of the beta 2 microglobulin molecule referred to as peptide J and a peptide (254-273) from human collagen Type II. Disease was induced by 2 immunizations of bovine type II collagen on day 0 (in CFA) and day 21 (in ICFA). The mice were scored daily for an Arthritic Index (AI) score. Therapy was initiated when the mice (n=8) had a group mean AI score of 3.5 +/- 0.1 and range of 1-6. CEL-2000 vaccine 33 or 100 nmole was administered on day 0 and 7 of therapy and etanercept 3 mg/kG was administered every other day for the 28 days unless otherwise noted. Mice were evaluated at least 3 times a week for A) footpad swelling and B) AI score. At the termination of the study, tissue sections were evaluated for C) histopathological parameters including 1) inflammation, as evidenced by accumulation of eosinophils, basophils, neutrophils and macrophages, 2) cartilage destruction 3) bone resorption, and 4) pannus membrane formation in the synovial space. D) Sera, collected at the start of therapy and 10 days later, were evaluated for levels of 22 cytokines / chemokines, as measured by the RayBiotech protein array.
Results: By all four parameters there was a statistically significant (p < 0.05 or better depending on the day of therapy and parameter being considered) benefit of the CEL-2000 vaccine therapy and to a lesser extent for etanercept therapy. CEL-2000 caused an increase in IL-12p70 and IL10 and reduction in disease associated serum levels of TNF-a, IL-17, IL-6, MCP-1 and IL-12p40. A number of cytokine changes were also seen with Enbrel although to a lesser degree
Conclusion: CEL-2000 vaccine administered as a therapy arrested the progression of RA disease and its efficacy was demonstrated by reduction in disease parameters (AI) and in the reduction of serum levels of pro-inflammatory cytokines.
Keywords: collagen and vaccines
Disclosure: D. Zimmerman, CeL SCI, 9 ; E. Talor, CEl sCI Corporation, 9 ; P. Taylor, None; S. O'Neill, None; A. Bendele, None; K. Rosenthal, None.
<< Previous Abstract in Session | Next Abstract in Session >>
See more of: Animal Models 1, Cytokines, T cells, Gene Targeting
See more of: ACR Poster Sessions
Good news to bring some interest into avii and should give us a little pop today! GLTA
news hasnt been released, but i did find a link to a synopsis of cvm's part. click the link in the msg from my last post. Also found this today:
http://www.wallstarticles.com/_customelements/uploadedResources/081229_CELSCICorp.CVM.pdf
heres the link to the info I found on the conference. I believe he does speak again, or has already and they haven't posted it yet:
http://acr.confex.com/acr/2009/webprogram/Paper10996.html
great game today tom!
Heres is all ive found so far on the conference:
Sunday, October 18, 2009: 9:00 AM - 11:00 AM
Hall D (Pennsylvania Convention Center)
Daniel Zimmerman, CEL SCI Corporation, Vienna, VA, Eyal Talor, CEL, Vienna, VA, Patricia Taylor, Northeastern Ohio colleges of Medicine, Rootstown, Sean O'Neill, Washington Biotech, Columbia, MD, Alison Bendele, BolderBiopath, Bolder, CO and Kenneth Rosenthal, Northeastern Ohio colleges of Medicine, Rootstown, OH
Presentation Number: 2
Poster Board Number: 2
Purpose: The collagen type II (bovine) (CIA) induced arthritis murine model is often used to evaluate treatments for rheumatoid arthritis (RA). Following initial induction, the disease progresses into a more classical cell and cytokine mediated pathogenesis. We will use this model to evaluate a new therapeutic vaccine for RA
Method: Male (7-8 week old) DBA/1J mice with CIA induced arthritis were either untreated or treated with the CEL-2000 L.E.A.P.S. experimental therapeutic vaccine or etanercept (Enbrel). CEL-2000 vaccine consists of 2 peptides of human origin, a segment of the beta 2 microglobulin molecule referred to as peptide J and a peptide (254-273) from human collagen Type II. Disease was induced by 2 immunizations of bovine type II collagen on day 0 (in CFA) and day 21 (in ICFA). The mice were scored daily for an Arthritic Index (AI) score. Therapy was initiated when the mice (n=8) had a group mean AI score of 3.5 +/- 0.1 and range of 1-6. CEL-2000 vaccine 33 or 100 nmole was administered on day 0 and 7 of therapy and etanercept 3 mg/kG was administered every other day for the 28 days unless otherwise noted. Mice were evaluated at least 3 times a week for A) footpad swelling and B) AI score. At the termination of the study, tissue sections were evaluated for C) histopathological parameters including 1) inflammation, as evidenced by accumulation of eosinophils, basophils, neutrophils and macrophages, 2) cartilage destruction 3) bone resorption, and 4) pannus membrane formation in the synovial space. D) Sera, collected at the start of therapy and 10 days later, were evaluated for levels of 22 cytokines / chemokines, as measured by the RayBiotech protein array.
Results: By all four parameters there was a statistically significant (p < 0.05 or better depending on the day of therapy and parameter being considered) benefit of the CEL-2000 vaccine therapy and to a lesser extent for etanercept therapy. CEL-2000 caused an increase in IL-12p70 and IL10 and reduction in disease associated serum levels of TNF-a, IL-17, IL-6, MCP-1 and IL-12p40. A number of cytokine changes were also seen with Enbrel although to a lesser degree
Conclusion: CEL-2000 vaccine administered as a therapy arrested the progression of RA disease and its efficacy was demonstrated by reduction in disease parameters (AI) and in the reduction of serum levels of pro-inflammatory cytokines.
Keywords: collagen and vaccines
Disclosure: D. Zimmerman, CeL SCI, 9 ; E. Talor, CEl sCI Corporation, 9 ; P. Taylor, None; S. O'Neill, None; A. Bendele, None; K. Rosenthal, None.
<< Previous Abstract in Session | Next Abstract in Session >>
See more of: Animal Models 1, Cytokines, T cells, Gene Targeting
See more of: ACR Poster Sessions
You must be buying a ton cuz there sure is alot of selling going on. With a product to market and another coming soon, it should not be going down like this. There are tons of bios with nothing in the market yet, or even close, and trade alot higher. Cant see why believers in the stock dont keep buying all these shares up at these levels. I have no money left to buy more, but might sell something else to get more here. Dont understand this action! Comments anyone?
let him know to send out a pr on how well its selling already. we need something to get this going the other way. Product is out and its dropping like a lead balloon.
2 bad black, it closed at 1.56, and with this weekends conference, u might have made a ton come monday! hope youre feeling better.
update on the balloon
they have it on the ground, but havent found the boy yet!
Not to change the subject. Im enjoying this nice rise in the pps. Is anyone watching the news. A 6 yr. old boy is flying over denver in a home made spaceship balloon. If u turn the news on u should be able to see it. Pretty cool, and they are not sure how to bring him down safely. Hes about 8000 ft up. Sorry if this bothers anyone, but i have a 7 yr old and it makes u wonder. His parents must be freaking! Go CVM!!!
China Crescent Enterprises, Inc. Signs $36 Million Letter of Intent to Provide Outsourcing Services
DALLAS, TX--(Marketwire - October 15, 2009) - China Crescent Enterprises, Inc. (OTCBB: CCTR) today announced that the Company has signed a letter of intent to provide outsourcing services to Aoyuan Electronic Co. ltd in Dalian, China, for $36 million over three years. China Crescent previously announced a $15 million letter of intent to provide outsourcing services to this company and, during the scheduled meetings this week, the scope of the agreement increased. The letter of intent announced today has replaced the previously announced letter of intent.
China Crescent has been conducting a series of meetings across four cities in China this week in conjunction with the Company's scheduled outsourcing management summit, primarily aimed at reviewing and developing the Company's growing technology outsourcing business. Earlier today, China Crescent announced the close of the summit and posted a Webcast to review the week's highlights. A link to the Webcast titled 'China Crescent Outsourcing Summit Review Webcast' is available at www.chinacrescent.com under Recent Webcasts.
China Crescent is a systems integration service provider in China that provides technology outsourcing services and sells and services brand name technologies such as Microsoft, Oracle, Cisco, IBM, HP and Dell in addition to selling and servicing innovative new technologies.
ditto Mr. green!
For some reason I believe the mm's have been working with the shorts to drop the pps to help them cover some because of the upcoming conference and expected positive news, as well as the work they are doing with the H1N1. If the conference goes as most of us expect, and positive news is released, this has a great shot at moving well above the 2.00 range, and many shorts will be SOL!! Lets hope the co. has been honest in their releases lately, and if so, anyone with half a brain knows this stock is worth alot more than 1.20's!! All IMO.
And dont forget the insider buying!
WHAT IS UP WITH ALL THE FRIGGIN SELLING? The product hit the internet and nyloxin is coming soon. Revenue is imminent, and idiots are selling it off. Why are you people selling, and below the ask? Make some money for yourselves and stop screwing the rest of us!
payment processing can take some time to get everything right. I know it has taken a day or 2 to get it set up as you need to make sure the gateway is figured properly and so on. Patience is the key, but this is a winner, and those who have held will be rewarded, IMO.
buy on the rumor, sell on the news type of situation, although not quite the same.
thankyou for your input. i was hoping this could replace some or all of the meds she takes now. She has the pain in her whole face, and the insurance co. will not pay for the surgery on the nerve because they have no proof of any problem, but thats why she has been diagnosed with it because all the tests came back negative. 2 edged sword.
wish i could reply privately, but i cant. She has had mri's, mra's, exrays, ct scans, blood work, urinalysis, and just about every test there is, and they havent found a thing. Thats why they diagnosed it as tri-geminal neuralgia. I was just hoping as a temporary thing she could try this versus continuing to take all this medicine they have her on. Its been going on for 9 years, and would really like to see her get some relief. With all the medicine, she sleeps most of her days away.
cris, im not asking for a diagnosis, I simply asked your opinion if you thought this would work for trigeminal neuralgia. Thanks.
Rev:
My sister suffers from tri-geminal neuralgia(spelling?) and was wondering if you thought this could help her. She suffers pain on both sides of her face in all 6 quadrants, and they have her on so many drugs its pathetic. She sleeps most of her life away now, and shes only 39. Im trying to find something that could help her and enable her to stop taking so many pills, as I dont want to see her develop kidney problems or worse down the road because of taking so many of them. Thanks.
whats the site? u have a link?
yea sure, look at crra and olbg, to name a few. Im sure those that invested and lost big on those will be buying this one too! lmao
Be cautious today, small cap society is pumping this one this morning. Could get volatile.
he writes articles on the street.com, and usually anything he bashes ends up going up. Most opinions are hes a paid basher helping to bring the price down on stocks so his cronies can get em cheaper.
No worries there. Im confident in CVM, and AF definately wont be swaying me into selling my shares. The ONLY valid point I have seen him make is that Multikline is taking so long to get a phrase III started. That could be gravy if they truly are being pushed in this H1N1 field. Not just prevention, but to supposedly be working on a cure for those already sick. That could be huge. All IMO!
Just read an article by Adam Feuerstein from the street.com and it appears he does not like CVM. Anyone out there know why, and is this a long running dispute, or just Adam being Adam? Heres the link for those interested:
http://www.thestreet.com/story/10606364/1/_msnh/biotech-mailbag-cel-sci-bioelectronics.html?cm_ven=MSNH&cm_cat=FREE&cm_ite=NA
its funny, as soon as someone starts talking about this stock, it starts going down. Somethings doesnt make sense, shouldnt it be going the other way?
hey learning:
can you email me, i have an idea i would like to discuss with you, since you live in my area I thought of you.
raisingkahne09@gmail.com
could be both good and bad. it could help the stock price with more investors, but it also opens it up to traders that love to come in and short the stock, which in turn costs us(the true investor) money! 6 of 1, half a dozen of the other.IMO
use your magic or whatever and get this thing moving. need to recoup some losses from that pos crra!
a lot of good people lost alot of money listening to the guys over at small cap society when they had this company as a featured company on their site and were really pumping it. Shortly after their pump, they deleted all the info about this company off of their site. I wonder how much they were paid to pump it, at the expense of the rest of us? Thanks Guys!!!
H1N1 Vaccine Is Top Flu Concern For U.S. Businesses
Published: Wednesday, 30 Sep 2009 | 7:36 AM ET Text Size By: CNBC.com
The number-one H1N1 flu concern among U.S. businesses is the availability of a vaccine for employees, according to a new survey by the Business Roundtable.
Getty Images
New York Public Information Campaign Warns of Swine Flu
--------------------------------------------------------------------------------
The organization also found that nearly 90-percent of businesses surveyed have activated or updated their crisis plans since an outbreak of the H1N1 influenza in April 2009. 35-percent of the survey respondents said they need more information about the severity of H1N1 pandemic flu compared to seasonal flu.
Member companies in the Business Roundtable represent one-third of the U.S. economy, including 10 million workers.
The group launched the survey several months ago in order to measure how well businesses were preparing for H1N1 and its potential effects on employees, customers, and operations.
"The findings are a reminder of how it is incumbent on the business community to work together with the government and other key parties to protect the health and well-being of our employees, fellow citizens, and communities in which we live and work," said Business Roundtable President John Castellani.
Business Roundtable President John Castellani on H1N1
RELATED LINKS
Current DateTime: 06:54:43 30 Sep 2009
LinksList Documentid: 33075484
Companies Plan for FluMask Makers Work 24/7Businesses Brace for Flu AbsenteeismAnti-Virals Key in Fighting H1N1
The organization is helping companies communicate H1N1 prevention advice to workers, using information from several government agencies, including the Centers for Disease Control and Prevention, the Department of Health and Human Services, the Small Business Adminstration, the Department of Homeland Security, and the Occupational Safety and Health Adminstration.
H1N1 Flu Information from CDC
Federal Government's flu.gov Guide
The U.S. Chamber of Commerce has also issued a major H1N1 preparedness guide for businesses, entitled "It's Not Flu as Usual." The report outlines key differences between seasonal flu and pandemic flu, an action plan for businesses to decrease the spread of flu, and information about Tamiflu, manufactured by Roche, and Relenza, produced by Glaxo Smith Kline [GSK 39.30 -0.33 (-0.83%) ], the two drugs most commonly used to treat H1N1.
HHS Secty Sebelius and Commerce Secty Locke on H1N1
Other groups advising businesses on the most effective ways to stop the spread of H1N1 include the Center for Infectious Disease Research and Policy (CIDRAP) and the National Association of County and City Health Officials (NACCHO).On a global scale, the World Health Organization and the United Nations have advised their members, including international businesses, on H1N1 prevention.
could be some profit taking, or selling to jump into something else for a quick buck. in the end, IMO, the longs will be greatly rewarded! This is a no-brainer, with huge potential, again IMO!!
Congrats all. I knew I should have gotten back in yesterday!
A possibility????
Sanofi CEO to Shop for Biotech, Vaccine, Nonprescription Deals
Share | Email | Print | A A A
By Michael Waldholz and Albertina Torsoli
Sept. 30 (Bloomberg) -- Sanofi-Aventis SA will continue “shopping” for acquisitions to build its vaccine, biotechnology, and nonprescription medicine businesses, as well as expand in emerging markets, Chief Executive Officer Chris Viehbacher said in an interview.
Sanofi has already spent 6.2 billion euros ($9 billion) this year to buy health-care companies and products as part of a strategy to bolster “five growth platforms,” Viehbacher, 49, said yesterday at the company’s New York offices. Viehbacher said Paris-based Sanofi is especially interested in expanding its vaccine operations, noting Johnson & Johnson’s purchase this week of 18 percent of Dutch vaccine company Crucell NV.
Viehbacher, who joined Sanofi from London-based GlaxoSmithKline Plc 10 months ago, is under pressure to expand as rivals merge and drugs accounting for about 20 percent of its sales face generic competition by 2013. Abbott Laboratories announced this week it will purchase of Solvay SA’s pharmaceutical unit for 4.8 billion euros. Pfizer Inc. agreed to buy Wyeth, and Merck & Co. said it will acquire Schering-Plough Corp. this year.
“There will be more shopping on the horizon,” Viehbacher said, declining to identify targets. Purchases must add to the company’s growth, Viehbacher said. He has said in the past that he is interested in acquisitions costing as much as 15 billion euros.
Vaccines are attractive because the market will double during the next five years, because the products aren’t readily reproduced by competitors and because of the investment required to build vaccine plants, Viehbacher said. Sanofi in July announced it would purchase Shantha Biotechnics, the Hyderabad, India-based maker of an experimental typhoid vaccine, and will keep looking for such acquisitions, he said.
where do i find dr. stockpick?
havent seen anyone pumping this over the last week or so. people know a good stock when they see it. great potential IMO!